Controlled release of the drug for osteoporosis from the surface of titanium implants coated with calcium titanate,Journal of Biomedical Materials Research Part B: Applied Biomaterials

当前位置： X-MOL 学术 › J. Biomed. Mater. Res. Part B Appl. Biomater. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Controlled release of the drug for osteoporosis from the surface of titanium implants coated with calcium titanate
Journal of Biomedical Materials Research Part B: Applied Biomaterials ( IF 3.2 ) Pub Date : 2021-07-21 , DOI: 10.1002/jbm.b.34919
Mariusz Sandomierski ₁ , Monika Zielińska ₁ , Tomasz Buchwald ₂ , Adam Patalas ₃ , Adam Voelkel ₁

Affiliation

The most popular drugs used to prevent osteoporosis that causes low mineral density and weakened microstructure of bones are bisphosphonates. Bisphosphonates can be administered in several ways, but each delivery method has drawbacks. Due to this, new methods of their delivery are being sought. Titanium implants coated with calcium titanate were prepared in this work as carriers for bisphosphonates. Such a modification has been proposed in order to improve the therapeutic properties of the implant. Slow release of the drug at a constant level will positively affect the recovery process and osteointegration. Furthermore, the drug will be slowly released very close to the area affected by osteoporosis. These studies were confirmed, using a variety of methods: EDS and XPS (to examine surface modification and drug sorption), Raman mapping (to proof the presence of the drug on the entire surface of the material) and UV-VIS spectroscopy (to determine bisphosphonate sorption and release profile). It was proved that the active substance (sorbed on the implant) could be completely released upon contact with body fluids within a month. The obtained results will allow for the production of endoprostheses dedicated to patients with osteoporosis in the future.

中文翻译：

从涂有钛酸钙的钛植入物表面控制释放骨质疏松症药物

用于预防导致矿物质密度低和骨骼微结构减弱的骨质疏松症的最流行药物是双膦酸盐。双膦酸盐可以通过多种方式给药，但每种给药方式都有缺点。因此，正在寻找新的交付方法。在这项工作中制备了涂有钛酸钙的钛植入物作为双膦酸盐的载体。已经提出了这样的修改以改善植入物的治疗特性。以恒定水平缓慢释放药物将对恢复过程和骨整合产生积极影响。此外，药物会在非常靠近骨质疏松症影响的区域缓慢释放。使用多种方法证实了这些研究：EDS 和 XPS（检查表面改性和药物吸附），拉曼图（以证明药物存在于材料的整个表面）和 UV-VIS 光谱（以确定双膦酸盐的吸附和释放曲线）。事实证明，活性物质（吸附在植入物上）可在一个月内与体液接触后完全释放。获得的结果将允许在未来生产专用于骨质疏松症患者的内置假体。

更新日期：2021-07-21

点击分享查看原文

点击收藏

阅读更多本刊最新论文